On September 6th, Weixinkang (603676.SH) announced that its wholly-owned subsidiary, Beijing Tibet Weixinkang Pharmaceutical Research and Development Co., Ltd. (referred to as 'Tibet Weixinkang'), has received the Drug Clinical Trial Approval Notice for Deoxycholic Acid Injection issued by the National Medical Products Administration. The deoxycholic acid injection declared by Tibet Weixinkang is developed with reference to Allergan Pharmaceuticals International/AbbVie S.r.l's Belkyra, which is indicated for improving moderate to severe contour elevation or excessive fullness caused by submental fat deposition in adults. The original product is currently not available on the domestic market.